Actelion needs to provide more info to FDA for Zavesca in Niemann-Pick disease
12 March 2010
Malini Guha
Please Login to read the full article.
12 March 2010
Malini Guha
Malini.guha@informa.com
The US FDA has issued Actelion with a complete response letter for its drug Zavesca (miglustat), for the treatment of progressive neurological manifestations in adults and children with Niemann-Pick type C (NP-C) disease – a rare, fatal neurodegenerative genetic disorder.
The FDA has...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
